Acist Medical acquires E-Z-EM products and systems

The acquisition includes the Empower line of contrast injector delivery systems, IRiS contrast management system and the EZ Chem point-of-care device, a unique chemistry device for testing serum creatinine levels.

Acist has acquired E-Z-EM assets as part of a transaction in which Bracco Diagnostics (BDI) merged with E-Z-EM. Both Acist and BDI (the US subsidiary of Bracco Imaging) are affiliates of the Bracco Group. BDI and Acist have executed a co-marketing agreement to support the sales of E-Z-EM’s injection systems and the EZ Chem Blood Analyzer.

Fulvio Renoldi Bracco, CEO of Acist Medical, said: “This is beneficial for both our customers and for the continued development of our business. Adding E-Z-EM’s portfolio, innovation, and technical expertise extends our ability to offer customers a more comprehensive and integrated range of products and services that can potentially deliver a total patient management solution.”